Recently, OxTium Technology has again secured tens of millions in Pre-A round investment, led by CDF-Capital with Jiangxi Financial Holdings following. The AI for Science investment track is heating up, and OxTium Technology has closed several consecutive funding rounds.
As a pioneer in AI for BioScience, OxTium Technology holds the globally advanced bioscience large model GeneLLM and has built a one-stop bioscience research platform BioFord™ and a bioscience intelligent agent system BioFord Agent™. Its technology spans CDF-Capital's two major investment areas—AI and healthcare—earning recognition. The core team, led by founder Dr. Jin Yongcheng, all come from Oxford University, with backgrounds in life sciences and artificial intelligence, forming a composite team.
AI for BioScience Industry Opportunities Emerge, OxTium Technology Accelerates
AI-driven science (AI for Science, AI4S) is called the "fifth paradigm" of scientific discovery. It inherits the essence of the previous four paradigms: from empirical observation to theoretical deduction, then to computational simulation and data-driven scientific discovery. The core of the fifth paradigm is that artificial intelligence is no longer just an auxiliary tool but becomes a "collaborator" and "accelerator" of scientific discovery.
Compared to chemistry and materials, AI seems to be a more "natural match" for bioscience. First, the life sciences field is experiencing a data explosion, from multi-omics sequencing raw data to expression information matrices, with data volumes increasing from TB to PB and beyond, providing essential training resources for AI. Second, in pharmaceutical R&D, precision medicine, synthetic biology, agricultural biology, and other biotech sectors, demand for AI for Science is strong, and industry R&D investment willingness is high.
Today, AI extracts hidden patterns from massive biological data, proposes new hypotheses, designs experiments, and accelerates the cycle of scientific research.
For example, DeepMind's AlphaFold 2 accurately predicts the three-dimensional structure of proteins from their amino acid sequences; EVo2, developed by the Arc Institute in the US, can understand and generate the language of life molecules, including multimodal biological data such as DNA, RNA, and proteins; OxTium Technology's GeneLLM large model can process multi-dimensional data including genomics, transcriptomics, proteomics, metagenomics, and epigenomics, greatly advancing basic research and translational outcomes.
The core input and processing objects of the above three models are sequence data of life molecules (amino acid sequences, nucleotide sequences), treating these sequences as a "language" for understanding and prediction.
Currently, OxTium Technology's self-developed GeneLLM large model (1.5 billion parameter version) has been pre-trained on 23 billion sequencing sequences and 3.45 trillion base pairs, aiding basic research in disease diagnosis, drug development, synthetic biology, and more, securing a place among global bioscience large models.
Providing Cutting-Edge AI Solutions to Reshape Life Sciences
AI is changing how scientists handle complex data and generate new scientific insights.
However, research resources remain unevenly distributed. Due to the enormous computational power and financial support required for training and running large models, many research groups or small-to-medium institutions face high costs and technical barriers that are difficult to overcome.
OxTium Technology's one-stop biological research platform BioFord™ integrates cutting-edge model tools and practical AI functions. Through model fine-tuning and inference tools, users do not need to train a massive model from scratch; they can call and personalize existing models with one click, completing complex data analysis and predictions in a short time. The platform supports basic research, medical diagnosis, biomanufacturing, breeding, environmental monitoring, and more, providing visual, high-precision, interpretable multi-omics AI solutions.
In the current exploration of AI for BioScience, "autonomous scientific discovery" centered on intelligent laboratories is a key area. OxTium Technology has launched the bioscience intelligent agent system BioFord Agent™, combining AI technology with automated experimental platforms (robots) to form an automated scientific discovery system capable of autonomously closing the "hypothesis-experiment-validation-new hypothesis" loop.
Addressing issues in traditional research such as scattered data, low experimental efficiency, dispersed computing power, and human errors, the introduction of AI agents throughout the research process—BioFord Agent™—uses automation, intelligence, and digitalization to solve traditional research pain points and build a new, more precise, and efficient research paradigm.
AI for BioScience is rapidly moving from the "proof of concept" stage to the "industrial application" stage. Focusing on AI for BioScience, OxTium Technology provides diverse and groundbreaking AI solutions with vast industrial prospects.
CDF-Capital Investment Perspective
The CDF-Capital investment team believes that OxTium Technology can serve various sub-scenarios in life sciences, enhancing and iterating R&D capabilities and efficiency, with enormous potential market size. Unlike previous AI model companies, OxTium Technology targets industry-specific foundational large models, developing models based on underlying data with strong application expansion capabilities. Moreover, due to the team's composite background in life sciences and AI, they possess unique advantages and barriers in data processing and analysis, making them more suitable for applications in life sciences. The company's industrialization progresses smoothly with strong technological innovation attributes. Meanwhile, as the industry enters a phase of rapid growth, the CDF-Capital team believes that OxTium Technology's future development space is full of imagination.